| Trial ID: | L5054 |
| Source ID: | NCT02592421
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02592421/results
|
| Conditions: |
Type II Diabetes Mellitus
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Plasma Glucose Concentration, Change from baseline to the last hour of the study (240-300 minutes) in plasma glucose concentration, Baseline to 240-300 minutes|Change in Endogenous Glucose Production (EGP), The change in endogenous glucose production is measured from baseline until the last hour of the study, Baseline to 240-300 minutes | Secondary: Change in Plasma Insulin During Measurement of EGP, Measurement of change in plasma insulin concentration during measurement of of EGP from baseline to last hour of the study, Baseline to 240-300 minutes|Change in Glucagon During EGP Measurement, Measurement of change in glucagon during EGP measurement from baseline to the last hour of the study, Baseline to 240-300 minutes
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-10-23
|
| Completion Date: |
2019-10-31
|
| Results First Posted: |
2019-12-18
|
| Last Update Posted: |
2020-09-17
|
| Locations: |
University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02592421
|
